轻微头创伤后立即与延迟性颅内出血风险:DOACs vs 华法林 vs 无抗凝
该多中心回顾性队列研究基于TriNetX全球协作网络(2014-2024),纳入急诊就诊并接受头颅CT的成人轻微头创伤患者,排除重大或穿透性创伤及近期神经外科手术者,按就诊前7天内使用DOAC、华法林或无抗凝分为三组,进行三对倾向评分匹配比较。主要终点为初始头颅CT阴性后30天内延迟性颅内出血。结果显示,与华法林相比,DOAC使用与更低的立即性颅内出血(3.8% vs 5.0%;OR 0.74,95%CI 0.67-0.83)、延迟性颅内出血(2.6% vs 3.3%;OR 0.79,95%CI 0.69-0.91)及30天死亡率(3.5% vs 4.4%;OR 0.80,95%CI 0.71-0.90)相关;与无抗凝相比,DOAC使用与颅内出血或死亡率无差异。临床意义在于,轻微头创伤的DOAC使用者安全性优于华法林使用者。
要点
- 成人轻微头创伤后,DOAC使用者立即性颅内出血3.8%低于华法林使用者5.0%(OR 0.74,95%CI 0.67-0.83)。
- DOAC使用者延迟性颅内出血2.6%低于华法林使用者3.3%(OR 0.79,95%CI 0.69-0.91)。
- DOAC使用者30天死亡率3.5%低于华法林使用者4.4%(OR 0.80,95%CI 0.71-0.90)。
- 与无抗凝者相比,DOAC使用与颅内出血或死亡率无差异。
- 研究为多中心回顾性队列,采用倾向评分匹配,结论需前瞻性验证。
适用人群与场景
- 成人(≥18岁)因轻微头创伤就诊急诊并接受头颅CT者。
- 排除重大或穿透性创伤及近期神经外科手术患者。
- 抗凝暴露定义为就诊前7天内使用DOAC(阿哌沙班、利伐沙班、达比加群、依度沙班)、华法林或无抗凝。
诊断标准与关键阈值
- 轻微头创伤定义原文未提及。
- 初始头颅CT阴性后30天内发生的颅内出血定义为延迟性颅内出血。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心回顾性队列研究,使用TriNetX全球协作网络(2014-2024)。
- 样本量:1,819,568次就诊,其中DOAC 34,307例(1.9%),华法林14,541例(0.8%),无抗凝1,770,720例(97.3%)。
- 主要终点:初始头颅CT阴性后30天内延迟性颅内出血;DOAC vs 华法林:2.6% vs 3.3%,OR 0.79(95%CI 0.69-0.91)。
- 关键次要终点:立即性颅内出血DOAC vs 华法林:3.8% vs 5.0%,OR 0.74(95%CI 0.67-0.83);30天死亡率DOAC vs 华法林:3.5% vs 4.4%,OR 0.80(95%CI 0.71-0.90)。
- DOAC vs 无抗凝:颅内出血或死亡率无差异。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:回顾性设计、观察性数据、可能存在残余混杂,原文未提及证据等级。
对床旁实践的改变
- 对于成人轻微头创伤接受头颅CT者,DOAC使用者的颅内出血和死亡风险低于华法林使用者,与无抗凝者相当。
- 该结论基于回顾性队列,不能直接推广为改变抗凝选择的前瞻性推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Minor head trauma frequently prompts emergency department (ED) evaluation and raises concern for intracranial hemorrhage (ICH) in anticoagulated patients. Comparative data on outcomes among patients receiving direct oral anticoagulants (DOACs), warfarin, or no anticoagulation remain limited.
METHODS: We conducted a multicenter retrospective cohort study using the TriNetX Global Collaborative Network (2014-2024). Adults (≥18 years) presenting to the ED with minor head trauma who underwent head CT were included; patients with major or penetrating trauma or recent neurosurgery were excluded. Patients were classified as receiving a DOAC (apixaban, rivaroxaban, dabigatran, edoxaban), warfarin, or no anticoagulant within 7 days prior to presentation. Three pairwise propensity-score-matched comparisons were performed. The primary outcome was delayed ICH within 30 days after an initially negative head CT. Secondary outcomes included immediate ICH, 30-day mortality, neurosurgical intervention, seizure, transfusion, and ED recidivism.
RESULTS: Among 1,819,568 encounters, 34,307 (1.9%) patients were on DOACs, 14,541 (0.8%) on warfarin, and 1,770,720 (97.3%) on neither. After matching, DOAC use was associated with lower immediate ICH (3.8% vs 5.0%; OR 0.74, 95% CI 0.67-0.83), delayed ICH (2.6% vs 3.3%; OR 0.79, 95% CI 0.69-0.91), and 30-day mortality (3.5% vs 4.4%; OR 0.80, 95% CI 0.71-0.90) compared with warfarin. Compared with no anticoagulation, DOAC use was not associated with differences in ICH or mortality.
CONCLUSION: In adults with minor head trauma, DOAC use was associated with a more favorable safety profile than warfarin.
参考来源
- O'Brien J, Tucker R, Nene R, et al. Risk of immediate and delayed intracranial hemorrhage after minor head trauma: DOACs vs warfarin vs no anticoagulation. Am J Emerg Med. 2026. PMID: 42468197. doi:10.1016/j.ajem.2026.07.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。